CeriBell (CBLL) vs TransMedics Group (TMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CeriBell (CBLL) has outperformed TransMedics Group (TMDX) over the past year, gaining 89.1% versus a loss of 33.1%. TransMedics Group is the larger company by market cap ($2.74 billion vs $888.5 million), about 3.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBLL | TMDX |
|---|---|---|
| Share price | $23.15 | $79.00 |
| Market cap | $888.45M | $2.74B |
| 1-day change | -1.41% | -2.55% |
| YTD return | +5.56% | -35.06% |
| 1-year return | +89.13% | -33.08% |
| 5-year return | — | +197.55% |
| P/E ratio (TTM) | — | 20.47 |
| Forward P/E | — | 35.05 |
| EPS (TTM) | $-1.76 | $3.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $605.49M |
| Revenue growth (YoY) | — | +37.13% |
| Net income (latest FY) | — | $190.29M |
| Gross margin | — | 59.92% |
| Operating margin | — | 17.93% |
| Net margin | — | 31.43% |
| 52-week high | $25.63 | $156.00 |
| 52-week low | $10.85 | $60.11 |
| Distance from 52-week high | -9.67% | -49.36% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +23.41% | +26.35% |
| Average volume | 370.29K | 820.41K |
| Shares outstanding | 38.38M | 34.68M |
| Employees | 327 | 898 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TransMedics Group is about 3.1 times larger than CeriBell by market value ($2.74B vs $888.45M).
- CBLL has outperformed TMDX by 122.2 percentage points over the past year.
- The two companies sit in different sectors: CeriBell in Health Care and TransMedics Group in Healthcare.
About CeriBell
CBLL stock →CeriBell, Inc. operates as a medical technology company in the United States.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 327 employees
About TransMedics Group
TMDX stock →TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Healthcare · Medical Devices · 898 employees
CBLL vs TMDX FAQ
Which is bigger, CeriBell or TransMedics Group?
TransMedics Group (TMDX) is larger, with a market capitalization of $2.74B compared with $888.45M for CeriBell (CBLL).
Which stock has performed better over the past year, CBLL or TMDX?
CBLL returned +89.13% over the past 12 months, compared with -33.08% for TMDX (price return, excluding dividends). Past performance does not predict future results.
Are CeriBell and TransMedics Group in the same industry?
No. CeriBell is in the Health Care sector, while TransMedics Group is in Healthcare.